On 28 July 2015, orphan designation (EU/3/15/1522) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for humanised IgG4 monoclonal antibody against extracellular tau for the treatment of progressive supranuclear palsy.
The sponsorship was transferred to Biogen Idec Limited, United Kingdom, in August 2017.
The sponsorship was transferred to Biogen Netherlands B.V. Netherlands, in April 2019.
Humanised IgG4 monoclonal antibody against extracellular tau
|Disease / condition||
Treatment of progressive supranuclear palsy
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;